Obesity directly affects kidney health and influences chronic kidney disease (CKD) risk and progression through contributing diseases such as type 2 diabetes and hypertension.

The Food and Drug Administration (FDA) announced that it has accepted the New Drug Application (NDA) for UGN-102 for intravesical solution for the treatment of low-grade intermediate-risk non-muscle ...

Nine statements developed, including performing 4 or more versus 3 or fewer needle passes in suspected malignant disease.

Of the about one-third receiving stimulant medication, 71.5% had difficulty filling prescription due to unavailability.